{"title":"Predictors of significant tricuspid regurgitation in atrial fibrillation: a meta-analysis.","authors":"Xiuxiu Zhang, Na Zhang, Jia Fu, Dapeng Yu","doi":"10.3389/fcvm.2025.1428964","DOIUrl":null,"url":null,"abstract":"<p><strong>Aims: </strong>Significant tricuspid regurgitation (TR) in atrial fibrillation (AF) patients is becoming a global issue, as it can lead to progressive right ventricular enlargement and heart failure, thereby increasing morbidity and mortality. This study aimed to evaluate potential predictors of significant TR in AF patients using open databases.</p><p><strong>Methods: </strong>PubMed, EMBASE, the Cochrane Library, and Web of Science were searched for relevant studies from inception to September 2023. Using STATA 14.0 statistical software, hazard ratios (HRs) were calculated for data synthesis. The potential predictors included clinical characteristics, echocardiography parameters, and prior comorbidities. Evidence certainty was evaluated based on the GRADE system.</p><p><strong>Results: </strong>In total, 12 studies involving almost 16,000 patients were included in this review. Female sex (HR = 2.14; 95% CI: 1.84-2.49; I<sup>2</sup> = 0.0%; <i>p</i> = 0.430), persistent atrial fibrillation (HR = 2.99; 95% CI: 2.47-3.61; I<sup>2</sup> = 0.0%; <i>p</i> = 0.896), left ventricular ejection fraction [standard mean difference (SMD) = -0.16; 95% CI:-0.30 to -0.03; I<sup>2</sup> = 69.8%; <i>p</i> < 0.000], age (HR = 1.07; 95% CI: 1.04-1.09; I<sup>2</sup> = 72.3%; <i>p</i> = 0.013), heart failure (HR = 1.86; 95% CI: 1.45-2.39; I<sup>2</sup> = 9.0%; <i>p</i> = 0.348), age ≥65 years (HR = 2.30; 95% CI: 1.63-3.25; I<sup>2</sup> = 55.1%; <i>p</i> = 0.108), chronic lung disease (HR = 1.33; 95% CI: 1.02-1.74; I<sup>2</sup> = 0.0%; <i>p</i> = 0.882), right ventricle fractional area change (SMD = 0.18; 95% CI: 0.01-0.36; I<sup>2</sup> = 0.0%; <i>p</i> = 0.440), systolic pulmonary arterial pressure (SMD = 0.97; 95% CI: 0.76-1.19; I<sup>2</sup> = 41.5%; <i>p</i> = 0.181), and proper ventricular systolic pressure (SMD = 1.07; 95% CI: 0.54-1.59; I<sup>2</sup> = 92.4%; <i>p</i> < 0.000) may negatively influence significant TR.</p><p><strong>Conclusions: </strong>This meta-analysis identified a potential negative influence of several clinical characteristics, echocardiography parameters, and previous comorbidities on significant TR. However, due to the low level of certainty of evidence, our analysis can only provide some guidance to practitioners and researchers. Caution is advised, and further validation is needed.</p>","PeriodicalId":12414,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"12 ","pages":"1428964"},"PeriodicalIF":2.8000,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11922934/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Cardiovascular Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fcvm.2025.1428964","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Aims: Significant tricuspid regurgitation (TR) in atrial fibrillation (AF) patients is becoming a global issue, as it can lead to progressive right ventricular enlargement and heart failure, thereby increasing morbidity and mortality. This study aimed to evaluate potential predictors of significant TR in AF patients using open databases.
Methods: PubMed, EMBASE, the Cochrane Library, and Web of Science were searched for relevant studies from inception to September 2023. Using STATA 14.0 statistical software, hazard ratios (HRs) were calculated for data synthesis. The potential predictors included clinical characteristics, echocardiography parameters, and prior comorbidities. Evidence certainty was evaluated based on the GRADE system.
Results: In total, 12 studies involving almost 16,000 patients were included in this review. Female sex (HR = 2.14; 95% CI: 1.84-2.49; I2 = 0.0%; p = 0.430), persistent atrial fibrillation (HR = 2.99; 95% CI: 2.47-3.61; I2 = 0.0%; p = 0.896), left ventricular ejection fraction [standard mean difference (SMD) = -0.16; 95% CI:-0.30 to -0.03; I2 = 69.8%; p < 0.000], age (HR = 1.07; 95% CI: 1.04-1.09; I2 = 72.3%; p = 0.013), heart failure (HR = 1.86; 95% CI: 1.45-2.39; I2 = 9.0%; p = 0.348), age ≥65 years (HR = 2.30; 95% CI: 1.63-3.25; I2 = 55.1%; p = 0.108), chronic lung disease (HR = 1.33; 95% CI: 1.02-1.74; I2 = 0.0%; p = 0.882), right ventricle fractional area change (SMD = 0.18; 95% CI: 0.01-0.36; I2 = 0.0%; p = 0.440), systolic pulmonary arterial pressure (SMD = 0.97; 95% CI: 0.76-1.19; I2 = 41.5%; p = 0.181), and proper ventricular systolic pressure (SMD = 1.07; 95% CI: 0.54-1.59; I2 = 92.4%; p < 0.000) may negatively influence significant TR.
Conclusions: This meta-analysis identified a potential negative influence of several clinical characteristics, echocardiography parameters, and previous comorbidities on significant TR. However, due to the low level of certainty of evidence, our analysis can only provide some guidance to practitioners and researchers. Caution is advised, and further validation is needed.
期刊介绍:
Frontiers? Which frontiers? Where exactly are the frontiers of cardiovascular medicine? And who should be defining these frontiers?
At Frontiers in Cardiovascular Medicine we believe it is worth being curious to foresee and explore beyond the current frontiers. In other words, we would like, through the articles published by our community journal Frontiers in Cardiovascular Medicine, to anticipate the future of cardiovascular medicine, and thus better prevent cardiovascular disorders and improve therapeutic options and outcomes of our patients.